FRM
NXTM

Fox Run Management’s NxStage Medical Inc. NXTM Stock Holding History

Fox Run Management’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-22,900
Closed -$600K – 831
2016
Q4 		$600K Buy
+22,900
New +$566K 0.32% 77
2016
Q3 		– Sell
-11,300
Closed -$245K – 782
2016
Q2 		$245K Buy
+11,300
New +$202K 0.12% 366

Other funds holding NXTM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fox Run Management's NXTM Position: Q1 2017 in Review

Fox Run Management sold out of NxStage Medical Inc. (NXTM) in Q1 2017, closing a stake of 22,900 shares — an estimated $600K sold.

Fox Run Management first reported a position in NXTM in Q2 2016 and held it in 2 quarters. The position peaked at $600K in Q4 2016. 171 funds tracked by Wall St. Rank hold NXTM as of Q1 2017.

  • Fox Run Management reported no remaining NxStage Medical Inc. position as of Q1 2017 after selling out during the quarter.
  • Fox Run Management sold 22,900 NxStage Medical Inc. shares in Q1 2017, an estimated $600K.
  • Fox Run Management first reported a position in NxStage Medical Inc. in Q2 2016 and held it in 2 quarters.
  • Fox Run Management's NxStage Medical Inc. position peaked at $600K in Q4 2016.
  • 171 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2017.

Based on Fox Run Management's 13F filing for Q1 2017, filed 17 Apr 2017.